CTRI/2024/04/066088Not yet recruitingNot Applicable
Lower Urinary Tract Dysfunction in Childhood Cancer Survivors - A Prospective Study
Swathi PM1 site in 1 country92 target enrollmentStarted: April 30, 2024Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Association between chemotherapeutic agents and their cumulative dose with development of LUTDS
Study Overview
Brief Summary
Chemotherapeutic agents commonly used in childhood cancer therapy may also cause long-term adverse effects, including lower urinary tract dysfunction (LUTD). LUTD can impact bladder function and lead to urinary incontinence, frequency, urgency, or difficulty in voiding. Despite several studies reporting a high prevalence of LUTD in childhood cancer survivors, the risk factors and optimal management strategies are not fully understood. This study aims to prospectively evaluate the prevalence, severity, risk factors, and management strategies of LUTD in childhood cancer survivors.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 5.00 Year(s) to 18.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •1.Survivors of childhood cancer 2.Age ≥ 5 years 3.Parents/guardians providing informed consent.
Exclusion Criteria
- •1.Survivors with congenital Genito urinary malformations, Genetic syndromes, spinal defects, and neurologic disorder 2.Parents who refuse to consent.
Outcomes
Primary Outcomes
Association between chemotherapeutic agents and their cumulative dose with development of LUTDS
Time Frame: 6 months
Secondary Outcomes
- assessing the risk factors for LUTD in cancer survivor children on chemotherapy(6 months)
Investigators
Swathi PM
Kasturba Medical College Manipal
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization MicroscopyNCT07313878University of Erlangen-Nürnberg Medical School30
Not yet recruiting
Not Applicable
Adverse effects on adrenal gland in cancer patients after chemotherapyCTRI/2024/05/066876Maulana Azad Medical College50
Not yet recruiting
Not Applicable
A Phase 3, Open label, Randomized and Controlled Study of Disitamab Vedotin with Pembrolizumab Versus platinum containing chemotherapy in participants with Urothelial cancer that Expresses HER2 that has spread through the body or spread near where it started.CTRI/2025/07/091091Seagen Inc., a wholly owned subsidiary of Pfizer400
Not yet recruiting
Not Applicable
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomABladder CancerNCT07413523Istituto Clinico Humanitas44
Completed
Not Applicable
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder CancerNCT07386847Pfizer1